https://scholars.lib.ntu.edu.tw/handle/123456789/597537
Title: | Genomic-guided precision therapy for soft tissue sarcoma | Authors: | Chen H.-W. WEI-WU CHEN |
Keywords: | genomics; precision medicine; sarcoma | Issue Date: | 2020 | Publisher: | BMJ Publishing Group | Journal Volume: | 5 | Journal Issue: | 2 | Source: | ESMO Open | Abstract: | Soft tissue sarcoma (STS), although heterogeneous in histopathology presentation, has mostly been treated with chemotherapy agents as one entity. Our understanding of crucial genomic alterations in different STS histologies and the advent of molecular-targeted agents have reshaped the treatment paradigm for advanced STS. Small-molecule inhibitors of c-KIT, plate-derived growth factor receptor alpha, c-MET, BRAF, anaplastic lymphoma kinase, ROS1 and colony-stimulating factor-1 receptor have been successfully validated in clinical studies to yield practice-changing results. Inhibitors of other novel genomic targets including mouse double minute 2 homolog, cyclin-dependent kinase 4/6, mitogen-activated protein kinase and epigenetic regulators are expected to be developed in the near future. Furthermore, with the advancement and accessibility of molecular diagnosis and next-generation sequencing, a genomic-based therapeutic approach should be widely applicable to advanced STS patients. This review will focus on the progress of genomic-guided therapy tailored to each molecular alteration of different STS histologies. ? Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85082663520&doi=10.1136%2fesmoopen-2019-000626&partnerID=40&md5=c5e39f4c1b8ac6c70531b5418aa5e3a1 https://scholars.lib.ntu.edu.tw/handle/123456789/597537 |
ISSN: | 2059-7029 | DOI: | 10.1136/esmoopen-2019-000626 | SDG/Keyword: | anaplastic lymphoma kinase; antineoplastic agent; B Raf kinase; cyclin dependent kinase 4; cyclin dependent kinase 6; cyclin dependent kinase inhibitor; mitogen activated protein kinase; platelet derived growth factor alpha receptor; protein MDM2; scatter factor receptor; stem cell factor receptor; transcription factor EZH2; tuberin; antineoplastic activity; cancer therapy; dermatofibrosarcoma protuberans; enzyme inhibition; gastrointestinal stromal tumor; gene mutation; genomics; giant cell tumor of tendon sheath; histopathology; human; molecular diagnosis; molecular fingerprinting; molecularly targeted therapy; nonhuman; perivascular epithelioid cell tumor; personalized medicine; plasma cell granuloma; Review; soft tissue sarcoma; genomics; pathology; personalized medicine; procedures; sarcoma; Genomics; Humans; Precision Medicine; Sarcoma |
Appears in Collections: | 醫學院附設醫院 (臺大醫院) |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.